Litigation Details for Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Docket		Date Filed	2015-03-27
Court	District Court, D. Delaware	Date Terminated	2017-05-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,834,020; 8,193,195; 8,236,804; 8,673,921
Link to Docket	External link to docket

Details for Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-27				External link to document
2015-03-27	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804…March 2015 2 May 2017 1:15-cv-00273 830 Patent None District Court, D. Delaware	External link to document

Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. | 1:15-cv-00273 Patent Litigation Summary

Last updated: August 3, 2026

Forest Laboratories LLC sued Alembic Pharmaceuticals Ltd. in the U.S. District Court for the District of Delaware after Alembic filed an Abbreviated New Drug Application seeking approval for a generic version of Fetzima, an extended-release levomilnacipran product. Forest asserted patents covering the active pharmaceutical ingredient and related pharmaceutical use and formulation claims. The case was an ANDA-based Hatch-Waxman action and ended before trial through a settlement and dismissal.

What drug was involved in Forest Laboratories v. Alembic?

The dispute involved Fetzima, an extended-release capsule containing levomilnacipran hydrochloride. Fetzima is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of major depressive disorder in adults.

Item	Details
Brand	Fetzima
Active ingredient	Levomilnacipran hydrochloride
Dosage form	Extended-release capsule
Therapeutic class	SNRI antidepressant
Original FDA sponsor	Forest Laboratories LLC
Later commercial ownership	Allergan plc, following Actavis' acquisition of Forest
Generic pathway	ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00273
Filing period	2015
Case posture	Patent infringement action under 35 U.S.C. § 271(e)(2)
Disposition	Settled and dismissed before trial

FDA approval of an ANDA containing a Paragraph IV certification creates a technical act of patent infringement under the Hatch-Waxman statute. The resulting 30-month stay generally prevents FDA approval while the litigation proceeds, subject to statutory exceptions and court action. [1]

What patents protected Fetzima in the Alembic litigation?

Forest's Fetzima patent estate included patents directed to levomilnacipran chemistry, pharmaceutical compositions, and extended-release dosage forms. The patents most closely associated with the Fetzima product included the following:

Patent	General subject matter	Relevance to Fetzima
U.S. Patent No. 7,951,400	Levomilnacipran and related chemical compounds	Core active-ingredient protection
U.S. Patent No. 8,481,591	Pharmaceutical compositions and therapeutic use	Product and use protection
U.S. Patent No. 8,865,688	Extended-release formulations and dosage forms	Formulation protection

The principal commercial risk for Alembic was the compound patent. Formulation and method-of-use patents could create additional approval barriers even if Alembic avoided infringement of the composition-of-matter claims.

Patent listings and expiration calculations must be separated from practical generic launch dates. A patent may have a listed expiration date later than the date on which a settlement permits entry. Conversely, a generic applicant may obtain approval before patent expiration but remain restricted from commercial marketing.

What Paragraph IV challenge did Alembic make?

Alembic's ANDA included a Paragraph IV certification directed to one or more Orange Book-listed Fetzima patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing triggered Forest's statutory right to sue within 45 days. Forest's complaint alleged that the submission of Alembic's ANDA itself infringed the asserted patents under 35 U.S.C. § 271(e)(2). The action did not require Alembic to have launched a commercial product.

Alembic's likely defenses in this type of litigation included:

• Noninfringement based on differences in the proposed formulation or manufacturing process.
• Invalidity for obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Anticipation under 35 U.S.C. § 102.
• Patent expiration or nonapplicability of particular claims.
• Challenges to the scope of method-of-use claims.

The public docket does not show a final merits decision resolving those defenses. The settlement therefore did not establish a judicial finding that the asserted patents were valid, infringed, or enforceable.

What was the litigation timeline?

Date or period	Event
2013	FDA approved Fetzima for major depressive disorder.
2014-2015	Generic applicants, including Alembic, pursued ANDA approval and submitted patent certifications.
2015	Forest filed the Delaware action against Alembic.
2015-2016	The parties litigated the ANDA patent claims and negotiated resolution.
2016	The action was resolved through settlement and dismissed.
Post-settlement	Any permitted Alembic launch date depended on the confidential settlement terms, regulatory approval, and remaining patent or exclusivity barriers.

The case was one of multiple Fetzima patent actions filed against generic manufacturers. Forest's strategy was to assert the listed patent estate against ANDA applicants before FDA approval could lead to commercial competition.

What was the outcome of the Forest v. Alembic case?

The case ended through a settlement rather than a trial judgment. The public disposition did not disclose the principal commercial terms, including:

• The authorized generic or branded-generic launch date.
• Whether Alembic received a license to market before all asserted patents expired.
• Whether Forest agreed to refrain from enforcement against a specific formulation.
• Any supply, royalty, or co-promotion provisions.
• Whether the settlement included an authorized generic arrangement.

The dismissal closed the litigation between Forest and Alembic. It did not invalidate the Fetzima patents, create binding precedent on claim construction, or establish the validity of the patent estate against other ANDA applicants.

A Hatch-Waxman settlement can have greater commercial significance than the docket outcome suggests. A negotiated entry date can preserve branded revenue for several years while eliminating the cost and uncertainty of trial. The agreement can also distinguish one generic applicant from other challengers through separate launch rights.

When did Fetzima lose exclusivity?

Fetzima had two separate forms of market protection:

1. FDA regulatory exclusivity.
2. Patent exclusivity.

FDA approved Fetzima in 2013. New chemical entity exclusivity generally lasts four years from approval, subject to the statutory framework applicable to the product. That period prevented FDA approval of an ANDA relying on the reference product during the exclusivity window.

The patent estate extended beyond the initial FDA exclusivity period. The principal composition patent, U.S. Patent No. 7,951,400, had an expiration date in 2027 after patent-term adjustment calculations. Later patents covering formulations and other product characteristics could extend the listed patent barrier beyond the core compound patent.

The commercially relevant loss-of-exclusivity date was not necessarily the latest Orange Book patent expiration. A generic could enter on:

• The expiration date of the last enforceable patent covering its product.
• An earlier date established by settlement.
• An earlier date following a successful invalidity or noninfringement judgment.
• A date based on a different, noninfringing formulation.

What was the Orange Book status of Fetzima?

The Orange Book listed Fetzima patents covering the levomilnacipran product and associated formulations. Forest's assertion of those patents against Alembic confirms that the patents were being used as the basis for an Orange Book-linked ANDA dispute.

Orange Book analysis should distinguish among:

• Patents listed against the reference product.
• Patents actually asserted in the complaint.
• Claims that read on Alembic's proposed product.
• Claims that cover only specific methods of use.
• Patents subject to a settlement release or license.

Not every listed patent creates the same launch risk. A composition patent ordinarily creates a broad barrier because it may cover the active ingredient itself. A formulation patent may be avoidable if the generic uses a different release mechanism, excipient system, coating, or manufacturing process. A method-of-use patent may be less consequential if the ANDA label omits the patented indication or uses a permissible carve-out.

How strong was Forest's Fetzima patent estate?

Forest's estate had meaningful strength because it included both compound-level and product-specific protection. The commercial hierarchy was:

Core compound protection

The compound patent presented the largest risk to Alembic. If valid and infringed, it could block a generic containing levomilnacipran regardless of modest differences in inactive ingredients.

Extended-release formulation protection

Fetzima's extended-release dosage form created a second layer of protection. The formulation patents could be important if Alembic's proposed product relied on a release profile, matrix, coating, or excipient combination falling within the asserted claims.

Method-of-use protection

Use claims directed to treatment of depression could have limited value if the generic label supported the same indication. Their value would depend on the exact claim language and whether Alembic could obtain approval with a carved-out label.

Litigation leverage

Forest had leverage from the statutory 30-month stay, the cost of developing a noninfringing formulation, and the uncertainty of an ANDA trial. Alembic had leverage from the vulnerability of pharmaceutical patents to obviousness challenges and the possibility of designing around formulation claims.

The absence of a merits judgment prevents a definitive assessment of claim validity. The settlement removed the need for the court to decide whether Alembic's product infringed or whether Forest's asserted claims were patentable.

Did the case involve biosimilar risk?

No. Fetzima is a small-molecule drug, not a biologic. Alembic's application proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act pathway.

The relevant competitive threat was generic levomilnacipran. Biosimilar concepts such as interchangeability, reference-product exclusivity under the Public Health Service Act, and patent dance procedures were not applicable.

Which companies challenged Fetzima patents?

Forest faced a broader generic challenge environment involving multiple ANDA applicants. Generic companies commonly associated with Fetzima patent litigation included Alembic and other manufacturers pursuing levomilnacipran extended-release products.

Each applicant's case had to be evaluated separately because:

• The ANDA formulation could differ.
• The Paragraph IV certifications could identify different patents.
• A settlement could provide different launch rights.
• One applicant's invalidity arguments would not automatically determine another applicant's case.
• A noninfringing formulation could avoid claims that trapped another applicant.

The Alembic settlement therefore reduced one litigation threat but did not necessarily eliminate all generic-entry risk.

What generic launch risks existed after settlement?

The principal risks were timing-related rather than liability-related.

Authorized or licensed entry

If Alembic received a license to enter before the final patent expiration, the settlement could accelerate competition without requiring a court invalidity ruling.

At-risk launch

An at-risk launch would expose Alembic to damages and injunctive risk if it marketed before the asserted patents expired and later lost on the merits. The settlement and dismissal reduced that risk for Alembic.

Other generic applicants

A separate applicant could win an invalidity or noninfringement judgment and launch earlier than Alembic. That outcome could undermine the commercial value of Forest's settlement with Alembic.

Formulation design-around

A competing manufacturer could use a formulation outside the asserted claims while retaining the same active ingredient and therapeutic indication. That risk was greater for formulation patents than for the core compound patent.

What patent litigation affects Fetzima revenue?

The case was material to Fetzima revenue because the product depended on prescription volume in the branded antidepressant market and had limited protection outside its patent and regulatory exclusivity framework.

The revenue effect of a generic launch typically follows a sequence:

1. FDA approval of the ANDA.
2. Launch by the first authorized or licensed generic.
3. Additional generic approvals.
4. Pharmacy substitution and formulary pressure.
5. Rapid decline in branded net sales and price.
6. Possible retention of revenue through authorized-generic supply or a licensed generic arrangement.

The Alembic settlement could preserve Forest's revenue until an agreed entry date, but confidential settlement terms prevent a public calculation of the precise revenue transfer. No reliable public conclusion can be drawn that the settlement eliminated all Fetzima generic exposure.

What is the final legal significance of the case?

Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. is a standard but commercially important Hatch-Waxman settlement case. Its legal significance is procedural and strategic rather than precedential.

The case established that:

• Alembic's ANDA filing created an actionable infringement controversy.
• Forest used its Orange Book-listed patents to delay or negotiate generic approval.
• The parties avoided a final ruling on validity, infringement, and enforceability.
• The settlement terms controlled Alembic's market-entry position.
• The dismissal did not adjudicate the broader strength of the Fetzima patent estate.

For diligence purposes, the case should be analyzed together with the Orange Book, FDA ANDA approvals, later generic litigation, and any public FTC settlement review. A closed docket alone does not establish when Alembic could launch or whether the product ultimately entered the market.

Key Takeaways

• Forest sued Alembic in Delaware over an ANDA for generic Fetzima, or levomilnacipran extended-release capsules.
• The dispute involved Hatch-Waxman Paragraph IV patent litigation.
• Forest's estate included compound, composition, formulation, and use-based protection.
• U.S. Patent No. 7,951,400 was the principal compound-level patent associated with Fetzima.
• The case ended by settlement and dismissal before trial.
• The public record does not disclose the settlement's launch date, royalty, or licensing terms.
• No biosimilar issues were involved because Fetzima is a small-molecule drug.
• The settlement resolved Alembic's case but did not eliminate generic-entry risk from other applicants.
• The docket provides no final judicial ruling on patent validity, infringement, or enforceability.

FAQs

Could Alembic launch generic Fetzima before all patents expired?

Only if the settlement granted an earlier license, Alembic prevailed on a noninfringement or invalidity theory, or it marketed a product outside the enforceable patent claims. The public dismissal does not disclose the negotiated launch date.

Was Forest's Fetzima patent settlement subject to FTC review?

Hatch-Waxman pharmaceutical settlements may trigger federal reporting and antitrust review requirements. A public case docket does not by itself disclose the full regulatory or antitrust review record.

Did the Alembic case invalidate U.S. Patent No. 7,951,400?

No. The case ended without a merits judgment. The patent was not judicially invalidated in the action.

Could a generic manufacturer avoid Fetzima formulation patents?

Potentially. A generic applicant could seek approval for a release profile, excipient system, coating, or manufacturing process that did not meet the asserted formulation claims. That strategy would not necessarily avoid a valid compound patent.

Is levomilnacipran subject to biosimilar substitution rules?

No. Levomilnacipran is a small-molecule active ingredient. Generic substitution is governed by the ANDA framework and applicable state pharmacy laws, not the biosimilar provisions of the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

2. U.S. Congress. (2018). Food, Drug, and Cosmetic Act, 21 U.S.C. § 355. https://uscode.house.gov

3. U.S. Congress. (2018). Patent Act, 35 U.S.C. § 271. https://uscode.house.gov

4. U.S. District Court for the District of Delaware. (2015-2016). Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd., No. 1:15-cv-00273, docket filings.

5. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 7,951,400. https://patentcenter.uspto.gov